SG10201901391RA - Induction of il-12 using immunotherapy - Google Patents
Induction of il-12 using immunotherapyInfo
- Publication number
- SG10201901391RA SG10201901391RA SG10201901391RA SG10201901391RA SG10201901391RA SG 10201901391R A SG10201901391R A SG 10201901391RA SG 10201901391R A SG10201901391R A SG 10201901391RA SG 10201901391R A SG10201901391R A SG 10201901391RA SG 10201901391R A SG10201901391R A SG 10201901391RA
- Authority
- SG
- Singapore
- Prior art keywords
- patient
- induction
- immunotherapy
- composition
- skews
- Prior art date
Links
- 230000006698 induction Effects 0.000 title abstract 3
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000000735 allogeneic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INDUCTION OF IL-12 USING IMMUNOTHERAPY The present invention relates to compositions and methods that promote the induction of IL-12 in a patient. The composition includes activated allogeneic cells that are administered to a patient with a disease such as cancer. Administration of the composition skews the patient's immune response to a Thl environment and produces detectable levels of IL-12 in the patient's plasma, without any IL-12 related toxicity. (FIGURE 1)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161482009P | 2011-05-03 | 2011-05-03 | |
US201161528484P | 2011-08-29 | 2011-08-29 | |
US201161564551P | 2011-11-29 | 2011-11-29 | |
US201261582881P | 2012-01-04 | 2012-01-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201901391RA true SG10201901391RA (en) | 2019-03-28 |
Family
ID=47108207
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2013081302A SG194753A1 (en) | 2011-05-03 | 2012-05-02 | Induction of il-12 using immunotherapy |
SG10201901391RA SG10201901391RA (en) | 2011-05-03 | 2012-05-02 | Induction of il-12 using immunotherapy |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2013081302A SG194753A1 (en) | 2011-05-03 | 2012-05-02 | Induction of il-12 using immunotherapy |
Country Status (11)
Country | Link |
---|---|
US (4) | US9233156B2 (en) |
EP (1) | EP2704732B1 (en) |
JP (2) | JP6393186B2 (en) |
KR (1) | KR102121492B1 (en) |
CN (2) | CN103687602A (en) |
AU (3) | AU2012250807A1 (en) |
BR (1) | BR112013028285A2 (en) |
CA (1) | CA2838046C (en) |
IL (1) | IL229177B (en) |
SG (2) | SG194753A1 (en) |
WO (1) | WO2012151279A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012250807A1 (en) | 2011-05-03 | 2013-12-12 | Immunovative Therapies, Ltd. | Induction of IL-12 using immunotherapy |
WO2015085162A1 (en) | 2013-12-05 | 2015-06-11 | Rfemb Holdings, Llc | Cancer immunotherapy by radiofrequency electrical membrane breakdown (rf-emb) |
JP6202339B2 (en) * | 2013-12-19 | 2017-09-27 | 国立研究開発法人国立精神・神経医療研究センター | GM-CSF producing T cell regulator and Th1 / Th2 immune balance regulator |
JP6723249B2 (en) | 2015-01-30 | 2020-07-15 | アールエフイーエムビー ホールディングス リミテッド ライアビリティ カンパニー | System and method for ablating soft tissue |
US11612426B2 (en) * | 2016-01-15 | 2023-03-28 | Immunsys, Inc. | Immunologic treatment of cancer |
US11389475B2 (en) * | 2017-07-14 | 2022-07-19 | Minzhen Xu | Method for inducing an M1 dominated immune response and pharmaceutical compositions |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2439003A1 (en) | 1978-10-20 | 1980-05-16 | Anvar | NEW OSTEOSYNTHESIS PARTS, THEIR PREPARATION AND THEIR APPLICATION |
US5766920A (en) | 1982-08-11 | 1998-06-16 | Cellcor, Inc. | Ex vivo activation of immune cells |
WO1988000970A2 (en) | 1986-08-08 | 1988-02-11 | Regents Of The University Of Minnesota | Method of culturing leukocytes |
PT89121A (en) | 1987-12-04 | 1989-12-29 | Du Pont | PROCESS FOR THE PREPARATION OF INTERLEUQUIN-2 FIXED AND INTERLEUKIN-2 CONTAINING AN EXTENSION IN THE TERMINAL-CARBOXYL WITH ACTIVITY OF INTERLEUQUIN-2 NATURAL |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
JPH0455577A (en) | 1990-06-22 | 1992-02-24 | Mitsubishi Electric Corp | Vibration controlling device of construction |
AU5729294A (en) | 1992-11-25 | 1994-06-22 | Tanox Biosystems, Inc. | Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules |
DE69430315T2 (en) | 1993-08-06 | 2002-11-21 | Epimmune, Inc. | METHODS FOR (EX VIVO) THERAPY BY MEANS OF PEPTIDE - ASSEMBLED ANTIQUE - PRESENTING CELLS FOR ACTIVATING CTL |
IL107483A0 (en) | 1993-11-03 | 1994-02-27 | Yeda Res & Dev | Bone marrow transplantation |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
ES2201177T3 (en) | 1995-03-08 | 2004-03-16 | The Scripps Research Institute | SYSTEM OF PRESENTATION OF ANTIGENS AND ACTIVATION OF T-CELLS. |
DE19545257A1 (en) | 1995-11-24 | 1997-06-19 | Schering Ag | Process for the production of morphologically uniform microcapsules and microcapsules produced by this process |
JPH09255577A (en) * | 1996-03-27 | 1997-09-30 | Dainippon Ink & Chem Inc | Agent for inducing interleukin-12 |
EP0969865B1 (en) | 1996-05-23 | 2006-12-06 | The Scripps Research Institute | Mhc class ii antigen-presenting systems and methods for activating cd4?+ t cells |
EP1018982B1 (en) | 1996-12-03 | 2005-03-09 | Osteobiologics, Inc. | Biodegradable polymeric film |
JP2002515756A (en) | 1997-01-31 | 2002-05-28 | ヘモソル インク. | Method of producing selected lymphocytes |
JP4132089B2 (en) | 1997-05-30 | 2008-08-13 | オステオバイオロジックス,インコーポレイテッド | Fiber reinforced porous biodegradable implantation device |
WO1999024045A1 (en) | 1997-11-10 | 1999-05-20 | Arch Development Corporation | Methods for treatment of tumors and tumor cells using ex vivo activated t cells |
JP2001054563A (en) | 1999-07-12 | 2001-02-27 | Isotis Bv | Suture |
US20030119185A1 (en) | 2000-02-24 | 2003-06-26 | Xcyte Therapies, Inc. | Activation and expansion of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
WO2001062092A1 (en) * | 2000-02-25 | 2001-08-30 | Thomas Jefferson University | Formulations and methods for using the same to elicit an immune response |
US20020127208A1 (en) | 2000-08-31 | 2002-09-12 | Waller Edmund K. | Method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease |
US6626950B2 (en) | 2001-06-28 | 2003-09-30 | Ethicon, Inc. | Composite scaffold with post anchor for the repair and regeneration of tissue |
US20030134415A1 (en) * | 2001-09-19 | 2003-07-17 | Gruenberg Micheal L. | Th1 cell adoptive immunotherapy |
AU2002342299A1 (en) | 2001-10-31 | 2003-05-12 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of | Generation of use of tc1 and tc2 cells |
WO2003053216A2 (en) | 2001-12-06 | 2003-07-03 | University Of Washington | Biodegradable, porous structures useful for growing living tissue, and methods of manufacture |
US20030175272A1 (en) | 2002-03-07 | 2003-09-18 | Medcell Biologics, Inc. | Re-activated T-cells for adoptive immunotherapy |
DE10230223A1 (en) | 2002-07-04 | 2004-01-22 | Tegenero Ag | Microparticles with CD28-specific monoclonal antibodies |
CN1399054A (en) * | 2002-09-03 | 2003-02-26 | 宋有财 | Rotary car parking plant |
US7435592B2 (en) * | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
US20110142887A1 (en) | 2009-12-15 | 2011-06-16 | Immunovative Therapies Ltd. | Methods and compositions for liquidation of tumors |
US7402431B2 (en) | 2004-03-01 | 2008-07-22 | Immunovative Therapies, Ltd. | T-cell therapy formulation |
US7371228B2 (en) | 2003-09-19 | 2008-05-13 | Medtronic Vascular, Inc. | Delivery of therapeutics to treat aneurysms |
US7592431B2 (en) | 2004-02-26 | 2009-09-22 | Immunovative Therapies, Ltd. | Biodegradable T-cell Activation device |
PT2573166T (en) | 2004-02-26 | 2016-07-07 | Immunovative Therapies Ltd | Methods for preparing t-cells for cell therapy |
US7446099B2 (en) | 2004-02-27 | 2008-11-04 | Nitto Denko Corporation | Compositions and methods for biodegradable polymer-peptide mediated transfection |
PT1749090T (en) * | 2004-03-01 | 2017-08-28 | Immunovative Therapies Ltd | Cell therapy formulation method and composition |
WO2005089127A2 (en) | 2004-03-05 | 2005-09-29 | The Trustees Of Columbia University In The City Of New York | Polymer-ceramic-hydrogel composite scaffold for osteochondral repair |
US8865224B2 (en) | 2004-10-14 | 2014-10-21 | Immunovative Therapies Ltd. | Allogeneic cellular immunotherapy for opportunistic infection |
EP2003978B1 (en) * | 2006-04-13 | 2014-06-11 | Immunovative Therapies, Ltd. | Allogeneic cell therapy for treatment of opportunistic infection |
US7972594B2 (en) * | 2006-11-13 | 2011-07-05 | Immunovative Therapies Ltd. | Ablative immunotherapy |
US20080112963A1 (en) | 2006-11-13 | 2008-05-15 | Immunovative Therapies, Ltd. | Ablative immunotherapy |
EP2025746A1 (en) * | 2007-08-16 | 2009-02-18 | Cell Med Research GMBH | Dendritic cells |
US20120128656A1 (en) | 2008-05-02 | 2012-05-24 | Immunovative Therapies, Ltd. | Vaccine compositions and methods |
AU2012250807A1 (en) | 2011-05-03 | 2013-12-12 | Immunovative Therapies, Ltd. | Induction of IL-12 using immunotherapy |
-
2012
- 2012-05-02 AU AU2012250807A patent/AU2012250807A1/en not_active Abandoned
- 2012-05-02 EP EP12779711.6A patent/EP2704732B1/en active Active
- 2012-05-02 KR KR1020137032017A patent/KR102121492B1/en active IP Right Grant
- 2012-05-02 CN CN201280021818.0A patent/CN103687602A/en active Pending
- 2012-05-02 BR BR112013028285A patent/BR112013028285A2/en not_active Application Discontinuation
- 2012-05-02 JP JP2014509386A patent/JP6393186B2/en active Active
- 2012-05-02 CA CA2838046A patent/CA2838046C/en active Active
- 2012-05-02 SG SG2013081302A patent/SG194753A1/en unknown
- 2012-05-02 SG SG10201901391RA patent/SG10201901391RA/en unknown
- 2012-05-02 US US13/581,745 patent/US9233156B2/en active Active
- 2012-05-02 CN CN201910193492.3A patent/CN109876138A/en active Pending
- 2012-05-02 WO PCT/US2012/036123 patent/WO2012151279A2/en active Application Filing
-
2013
- 2013-10-31 IL IL229177A patent/IL229177B/en active IP Right Grant
-
2015
- 2015-12-08 US US14/962,728 patent/US11045541B2/en active Active
-
2017
- 2017-04-12 JP JP2017079200A patent/JP6615148B2/en active Active
- 2017-06-15 AU AU2017204058A patent/AU2017204058A1/en not_active Abandoned
-
2019
- 2019-07-01 AU AU2019204699A patent/AU2019204699A1/en not_active Abandoned
-
2021
- 2021-05-20 US US17/326,009 patent/US11883490B2/en active Active
-
2024
- 2024-01-17 US US18/415,111 patent/US20240148865A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN109876138A (en) | 2019-06-14 |
EP2704732B1 (en) | 2020-03-04 |
WO2012151279A2 (en) | 2012-11-08 |
BR112013028285A2 (en) | 2017-01-10 |
US20160089433A1 (en) | 2016-03-31 |
US11045541B2 (en) | 2021-06-29 |
US11883490B2 (en) | 2024-01-30 |
EP2704732A4 (en) | 2015-02-25 |
AU2017204058A1 (en) | 2017-07-13 |
JP2017141287A (en) | 2017-08-17 |
JP6615148B2 (en) | 2019-12-04 |
US9233156B2 (en) | 2016-01-12 |
AU2019204699A1 (en) | 2019-07-18 |
IL229177B (en) | 2020-07-30 |
JP2014513126A (en) | 2014-05-29 |
US20130101551A1 (en) | 2013-04-25 |
CN103687602A (en) | 2014-03-26 |
US20210268106A1 (en) | 2021-09-02 |
SG194753A1 (en) | 2013-12-30 |
WO2012151279A3 (en) | 2012-12-20 |
US20240148865A1 (en) | 2024-05-09 |
CA2838046C (en) | 2023-03-07 |
JP6393186B2 (en) | 2018-09-19 |
KR102121492B1 (en) | 2020-06-11 |
CA2838046A1 (en) | 2012-11-08 |
EP2704732A2 (en) | 2014-03-12 |
IL229177A0 (en) | 2013-12-31 |
AU2012250807A1 (en) | 2013-12-12 |
KR20140041517A (en) | 2014-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
AU2018253544A1 (en) | Methods for treating or preventing asthma by administering an IL-4R antagonist | |
PH12015501067A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
MX2014009757A (en) | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy. | |
EP4233545A3 (en) | Synergistic bacterial compositions and methods of production and use thereof | |
EP3904502A3 (en) | Compositions and methods | |
BR112015014462A2 (en) | pharmaceutical vectorization of a mammalian cyclic dinucleotide signaling pathway | |
SG10201901391RA (en) | Induction of il-12 using immunotherapy | |
NZ709260A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
MX2013004817A (en) | Inflammatory disease. | |
EP2576578A4 (en) | Polymorphs of 2'-o-fucosyllactose and producing thereof | |
GB201106743D0 (en) | Novel compounds | |
MX2012007806A (en) | Pharmaceutical compositions for oral administration of insulin peptides. | |
IN2014MN00333A (en) | ||
MX2014006126A (en) | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities. | |
WO2014205199A3 (en) | Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency | |
MX2013004061A (en) | Cyclosporin analogs. | |
GB201213267D0 (en) | Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases | |
MX2020014208A (en) | Optimised subcutaneous therapeutic agents. | |
IN2014DN06737A (en) | ||
MX2013004062A (en) | Cyclosporin analogs. | |
UA112420C2 (en) | APOPTOSIS INHIBITORS AND THEIR APPLICATIONS | |
MX2016008027A (en) | Use of laquinimod to delay huntington's disease progression. | |
AU2012253610A8 (en) | Compositions and methods for treating cancer |